Joshua D Palmer1, Deepak Bhamidipati2, Andrew Song3, Harriet B Eldredge-Hindy4, Joshua Siglin5, Tu D Dan6, Colin E Champ7, Isabella Zhang8, Voichita Bar-Ad3, Lyndon Kim9, Jon Glass9, James J Evans9, David W Andrews9, Maria Werner-Wasik3, Wenyin Shi10. 1. Department of Radiation Oncology, The James Cancer Hospital and Solove Research Institute, Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA. 2. Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, 19107, USA. 3. Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. 4. Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louiville, Louiville, KY, 40202, USA. 5. Department of Radiation Oncology, Hillman Cancer Center at UPMC Altoona, Altoona, PA, 16601, USA. 6. Department of Radiation Oncology, Harold C Simmons Comprehensive Cancer Center, University of Texas Southwestern, Dallas, TX, 75390, USA. 7. Department of Radiation Oncology, UPMC Cancer Center at UPMC St. Margaret, University of Pittsburgh, Pittsburgh, PA, 15215, USA. 8. Department of Radiation Medicine, North Shore-Long Island Jewish Medical Center, New Hyde Park, NY, 11040, USA. 9. Department of Neurological Surgery, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. 10. Department of Radiation Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, 19107, USA. Wenyin.Shi@jeffersonhospital.org.
Abstract
PURPOSE/ OBJECTIVES: We report the outcomes of the largest cohort to date of patients receiving both bevacizumab (BEV) and fractionated stereotactic radiotherapy (FSRT) for progressive or recurrent high grade glioma (HGG). Furthermore, the sequence of these two treatment regimens was analyzed to determine an optimal treatment paradigm for recurrent HGG. MATERIALS/ METHODS: After Institutional Review Board approval, patients with pathologically confirmed WHO grade III anaplastic astrocytoma (AA) or IV glioblastoma multiforme (GBM) glioma who subsequently underwent re-irradiation at recurrence with FSRT were retrospectively reviewed. Patients from this group who had received BEV were also identified. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were analyzed as study endpoints. Date of recurrence was defined as the date of radiographic evidence of progressive/recurrent disease. Kaplan-Meier curves were generated utilizing a log-rank test with a p-value ≤ 0.05 considered significant to compare treatment sequences in terms of survival outcomes. RESULTS: A total of 118 patients with recurrent/progressive HGG (GBM = 87, AA = 31) had received both BEV and FSRT. Patient characteristics were as follows: median KPS at recurrence was 80 (range 50-100); median age at recurrence was 57 years; median time to radiographic recurrence/progression was 10.8 months (mo) and 33.1% of patients had surgery for recurrence. The median time from the start of BEV to FSRT was 6.4 months and from FSRT to the start of BEV was 5.1 months. For the entire cohort, median overall survival (OS) was 26.7 months and median survival time (MST) from recurrence was 13.8 months (24.4 months and 11.9 months for GBM only). In patients that received BEV prior to FSRT (n = 50), median OS and MST from recurrence were 25.2 and 13.3 months respectively. In patients receiving FSRT first (n = 56), median OS and MST from recurrence were 28.8 months and 13.9 months, respectively. Sequencing of BEV and FSRT at recurrence was not significantly associated with OS (p = 0.08) or median survival from recurrence (p = 0.75). CONCLUSIONS: The combination of FSRT and BEV for recurrent/progressive HGG provides promising results in terms of overall survival and survival from recurrence. Combining these treatment modalities appears to improve upon the historic outcomes of either treatment alone. The outcomes data from this study support the ongoing RTOG trial exploring the combination of BEV and FSRT for recurrent HGG.
PURPOSE/ OBJECTIVES: We report the outcomes of the largest cohort to date of patients receiving both bevacizumab (BEV) and fractionated stereotactic radiotherapy (FSRT) for progressive or recurrent high grade glioma (HGG). Furthermore, the sequence of these two treatment regimens was analyzed to determine an optimal treatment paradigm for recurrent HGG. MATERIALS/ METHODS: After Institutional Review Board approval, patients with pathologically confirmed WHO grade III anaplastic astrocytoma (AA) or IV glioblastoma multiforme (GBM) glioma who subsequently underwent re-irradiation at recurrence with FSRT were retrospectively reviewed. Patients from this group who had received BEV were also identified. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were analyzed as study endpoints. Date of recurrence was defined as the date of radiographic evidence of progressive/recurrent disease. Kaplan-Meier curves were generated utilizing a log-rank test with a p-value ≤ 0.05 considered significant to compare treatment sequences in terms of survival outcomes. RESULTS: A total of 118 patients with recurrent/progressive HGG (GBM = 87, AA = 31) had received both BEV and FSRT. Patient characteristics were as follows: median KPS at recurrence was 80 (range 50-100); median age at recurrence was 57 years; median time to radiographic recurrence/progression was 10.8 months (mo) and 33.1% of patients had surgery for recurrence. The median time from the start of BEV to FSRT was 6.4 months and from FSRT to the start of BEV was 5.1 months. For the entire cohort, median overall survival (OS) was 26.7 months and median survival time (MST) from recurrence was 13.8 months (24.4 months and 11.9 months for GBM only). In patients that received BEV prior to FSRT (n = 50), median OS and MST from recurrence were 25.2 and 13.3 months respectively. In patients receiving FSRT first (n = 56), median OS and MST from recurrence were 28.8 months and 13.9 months, respectively. Sequencing of BEV and FSRT at recurrence was not significantly associated with OS (p = 0.08) or median survival from recurrence (p = 0.75). CONCLUSIONS: The combination of FSRT and BEV for recurrent/progressive HGG provides promising results in terms of overall survival and survival from recurrence. Combining these treatment modalities appears to improve upon the historic outcomes of either treatment alone. The outcomes data from this study support the ongoing RTOG trial exploring the combination of BEV and FSRT for recurrent HGG.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: Kyle C Cuneo; James J Vredenburgh; John H Sampson; David A Reardon; Annick Desjardins; Katherine B Peters; Henry S Friedman; Christopher G Willett; John P Kirkpatrick Journal: Int J Radiat Oncol Biol Phys Date: 2011-04-12 Impact factor: 7.038
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Mark R Gilbert; Meihua Wang; Kenneth D Aldape; Roger Stupp; Monika E Hegi; Kurt A Jaeckle; Terri S Armstrong; Jeffrey S Wefel; Minhee Won; Deborah T Blumenthal; Anita Mahajan; Christopher J Schultz; Sara Erridge; Brigitta Baumert; Kristen I Hopkins; Tzahala Tzuk-Shina; Paul D Brown; Arnab Chakravarti; Walter J Curran; Minesh P Mehta Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Philip H Gutin; Fabio M Iwamoto; Kathryn Beal; Nimish A Mohile; Sasan Karimi; Bob L Hou; Stella Lymberis; Yoshiya Yamada; Jenghwa Chang; Lauren E Abrey Journal: Int J Radiat Oncol Biol Phys Date: 2009-01-23 Impact factor: 7.038
Authors: Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Corbin A Helis; Shih-Ni Prim; Christina K Cramer; Roy Strowd; Glenn J Lesser; Jaclyn J White; Stephen B Tatter; Adrian W Laxton; Christopher Whitlow; Hui-Wen Lo; Waldemar Debinski; James D Ververs; Paul J Black; Michael D Chan Journal: Neurooncol Pract Date: 2022-05-02
Authors: T Gupta; M Maitre; P Maitre; J S Goda; R Krishnatry; A Chatterjee; A Moiyadi; P Shetty; S Epari; A Sahay; V Patil; R Jalali Journal: Clin Transl Oncol Date: 2021-02-02 Impact factor: 3.405
Authors: Daniel P Kulinich; John P Sheppard; Thien Nguyen; Aditya M Kondajji; Ansley Unterberger; Courtney Duong; Adam Enomoto; Kunal Patel; Isaac Yang Journal: Acta Neurochir (Wien) Date: 2021-04-02 Impact factor: 2.216
Authors: Lucio De Maria; Lodovico Terzi di Bergamo; Alfredo Conti; Kazuhiko Hayashi; Valentina Pinzi; Taro Murai; Rachelle Lanciano; Sigita Burneikiene; Michela Buglione di Monale; Stefano Maria Magrini; Marco Maria Fontanella Journal: Front Oncol Date: 2021-03-29 Impact factor: 6.244
Authors: Tulika Ranjan; Candace M Howard; Alexander Yu; Linda Xu; Khaled Aziz; David Jho; Jodi Leonardo; Muhammad A Hameed; Stephen M Karlovits; Rodney E Wegner; Russell Fuhrer; Seth T Lirette; Krista L Denning; Jagan Valluri; Pier Paolo Claudio Journal: Transl Oncol Date: 2020-03-17 Impact factor: 4.243
Authors: Joseph Chan; Dasantha Jayamanne; Helen Wheeler; Mustafa Khasraw; Matthew Wong; Marina Kastelan; Lesley Guo; Michael Back Journal: Clin Transl Radiat Oncol Date: 2020-03-09